Clinical Study Results – 214 Patient Study Data
William P. Fitch lll, M.D., Board Certified Urologist and Surgeon, wrote and presented an abstract at Boston University on the efficacy of prescribed transdermal verapamil. The abstract was published in the International Journal of Impotence Research, Sept., 1999. Clinical studies are ongoing and new data will be posted on this site as soon as it becomes available.
Verapamil topical compound *(40mg) was applied twice daily to the penises of 214 patients presenting with symptoms of Peyronie’s Disease. Patients were followed for one to six months for change in curvature, plaque size, quality of erection, pain relief and side effects.
Curvature: 71.4% noticed decreased curvature
Erection Quality: 86.5% had measurable improvement of overall quality and rigidity of erection.
Pain: 100% reported complete relief of pain
Side Effects: 1.4% (3 patients) developed contact dermatitis which improved in 2 patients with topical corticosteroid application.
These results led Dr. Fitch to conclude, “Topical Verapamil appears to be an effective and well tolerated drug for the treatment of Peyronie’s Disease.”
*This study was conducted with an 8% compound. The pharmacy now provides a 15% (75mg) per dose compound that has proven to be more efficacious.